Emerging Molecular Targets for Intravascular Imaging of High-Risk Plaques

Current Cardiovascular Imaging Reports

Volumn 3, Issue 4, 2010, Pages 237-247

  Kim, Jin Won ^a,b   Jaffer, Farouc A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Korea University College of Medicine   (South Korea)

Author keywords

Atherosclerosis; Fluorescence; Intravascular; Molecular imaging; Thrombosis

Indexed keywords

EID: 79958861062     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-010-9028-6     Document Type: Review

References (47)

1. Nissen SE: The vulnerable plaque "hypothesis": promise, but little progress. JACC Cardiovasc Imaging 2009, 2: 483-485.
2. Choi SH, Chae A, Chen CH, et al.: Emerging approaches for imaging vulnerable plaques in patients. Curr Opin Biotechnol 2007, 18: 73-82.
3. Libby P: Inflammation in atherosclerosis. Nature 2002, 420: 868-874.
4. Jaffer FA, Libby P, Weissleder R: Molecular imaging of cardiovascular disease. Circulation 2007, 116: 1052-1061.
5. Sanz J, Fayad ZA: Imaging of atherosclerotic cardiovascular disease. Nature 2008, 451: 953-957.
6. Calfon MA, Vinegoni C, Ntziachristos V, et al.: Intravascular near-infrared fluorescence molecular imaging of atherosclerosis: toward coronary arterial visualization of biologically high-risk plaques. J Biomed Optics 2010, 15: 011107.
7. Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nat Med 2003, 9: 123-128.
8. Ntziachristos V, Ripoll J, Wang LV, et al.: Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 2005, 23: 313-320.
9. Jaffer FA, Libby P, Weissleder R: Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29: 1017-1024.
10. Ntziachristos V, Tung CH, Bremer C, et al.: Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002, 8: 757-760.
11. Nahrendorf M, Zhang H, Hembrador S, et al.: Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117: 379-387.
12. •• Jaffer FA, Vinegoni C, John MC, et al.: Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 2008, 118: 1802-1809. This is the first in vivo study of catheter-based intravascular NIRF molecular imaging in human coronary-sized vessels.
13. Lindner JR: Contrast ultrasound molecular imaging of inflammation in cardiovascular disease. Cardiovasc Res 2009, 84: 182-189.
14. Hamilton AJ, Huang SL, Warnick D, et al.: Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 2004, 43: 453-460.
15. Kornmann LM, Reesink KD, Reneman RS, et al.: Critical appraisal of targeted ultrasound contrast agents for molecular imaging in large arteries. Ultrasound Med Biol 2010, 36: 181-191.
16. Tang TY, Muller KH, Graves MJ, et al.: Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 2009, 29: 1001-1008.
17. Wilensky RL, Song HK, Ferrari VA: Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J Am Coll Cardiol 2006, 47(8 Suppl): C48-C56.
18. Regar E, Hennen B, Grube E, et al.: First-in-man application of a miniature self-contained intracoronary magnetic resonance probe. A multi-centre safety and feasibility trial. EuroIntervention 2006, 2: 77-83.
19. Khadim G, Nanjundappa A, Dieter R.: Intravascular MRI. Curr Cardiovasc Imaging Rep 2009, 2: 293-299.
20. Strauss HW, Mari C, Patt BE, et al.: Intravascular radiation detectors for the detection of vulnerable atheroma. J Am Coll Cardiol 2006, 47(8 Suppl): C97-C100.
21. Jaffer FA, Libby P, Weissleder R: Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol 2006, 47: 1328-1338.
22. Chen J, Tung CH, Mahmood U, et al.: In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002, 105: 2766-2771.
23. Kim DE, Kim JY, Schellingerhout D, et al.: Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging. Arterioscler Thromb Vasc Biol 2010, 30: 449-456.
24. Deguchi JO, Aikawa M, Tung CH, et al.: Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006, 114: 55-62.
25. Lutgens SP, Cleutjens KB, Daemen MJ, et al.: Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007, 21: 3029-3041.
26. • Jaffer FA, Kim DE, Quinti L, et al.: Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 2007, 115: 2292-2298. This article discusses the usefulness of lesion-specific proteinase-activatable NIRF imaging for detection of plaque CatK activity.
27. Blum G, von Degenfeld G, Merchant MJ, et al.: Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 2007, 3: 668-677.
28. Jaffer FA, Nahrendorf M, Sosnovik D, et al.: Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol Imaging 2006, 5: 85-92.
29. Nahrendorf M, Jaffer FA, Kelly KA, et al.: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114: 1504-1511.
30. Kaufmann BA, Sanders JM, Davis C, et al.: Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 2007, 116: 276-284.
31. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al.: Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004, 350: 1472-1473.
32. Sosnovik DE, Caravan P: Molecular MRI of atherosclerotic plaque with targeted contrast agents. Curr Cardiovasc Imaging Rep 2009, 2: 87-94.
33. • Edgington LE, Berger AB, Blum G, et al.: Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat Med 2009, 15: 967-973. This study demonstrates the potential of a caspase-specifc activity-based probe for imaging of apopotosis.
34. Matter CM, Schuler PK, Alessi P, et al.: Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res 2004, 95: 1225-1233.
35. Waldeck J, Hager F, Holtke C, et al.: Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alpha v beta3 integrin-targeted fluorochrome. J Nucl Med 2008, 49: 1845-1851.
36. Winter PM, Morawski AM, Caruthers SD, et al.: Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta(3)-integrin-targeted nanoparticles. Circulation 2003, 108: 2270-2274.
37. Vavuranakis M, Kakadiaris IA, O'Malley SM, et al.: A new method for assessment of plaque vulnerability based on vasa vasorum imaging, by using contrast-enhanced intravascular ultrasound and differential image analysis. Int J Cardiol 2008, 130: 23-29.
38. Vengrenyuk Y, Carlier S, Xanthos S, et al.: A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci U S A 2006, 103: 14678-14683.
39. Virmani R, Burke AP, Farb A, Kolodgie FD: Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47(8 Suppl): C13-C18.
40. •• Aikawa E, Nahrendorf M, Figueiredo JL, et al.: Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007, 116: 2841-2850. By simultaneous mapping of NIRF signals with CLIO-VT 680 and OsteoSense, sequential intravital fluorescence microscopy showed plaque inflammation preceded arterial microcalcification.
41. Briley-Saebo KC, Shaw PX, Mulder WJ, et al.: Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008, 117: 3206-3215.
42. Schwartz RS, Burke A, Farb A, et al.: Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology. J Am Coll Cardiol 2009, 54: 2167-2173.
43. Rittersma SZ, van der Wal AC, Koch KT, et al.: Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation 2005, 111: 1160-1165.
44. Jaffer FA, Tung CH, Gerszten RE, et al.: In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler Thromb Vasc Biol 2002, 22: 1929-1935.
45. Jaffer FA, Tung CH, Wykrzykowska JJ, et al.: Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation 2004, 110: 170-176.
46. Flaumenhaft R, Tanaka E, Graham GJ, et al. Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation 2007, 115: 84-93.
47. McCarthy JR, Patel P, Botnaru I, et al.: Multimodal nanoagents for the detection of intravascular thrombi. Bioconjug Chem 2009, 20: 1251-1255.